streptomycin

Streptomycin sulfate (Phytomycin) is a sulfate salt of streptomycin that is a protein synthesis inhibitor.

Streptomycin (Agrept) is an aminoglycoside antibiotic derived from Streptomyces, a blocker of stretch-activated and mechanically-sensitive ion channels in neurons and cardiomyocytes, with anti-tuberculosis activity. It strongly binds to nucleic acids, interferes with protein synthesis, and can be used to study Mycobacterium tuberculosis infections.

Kanamycin sulfate (Kanamycin monosulfate) is an aminoglycoside antibiotic that interferes with protein synthesis by binding to the 70S ribosomal subunit of bacteria. Kanamycin sulfate exhibits antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as mycoplasmas.

Senfolomycin B exhibits activity against Gram-positive bacteria and mycobacteria, as well as effectiveness against penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-antibiotic-resistant Staphylococcus aureus. Additionally, Senfolomycin A demonstrates weaker activity against Gram-negative bacteria.

Paulomycin B exhibits activity against gram-positive bacteria and inhibits Staphylococcus aureus that is resistant to penicillin, streptomycin, neomycin, and macrolide antibiotics.

Paulomycin A2 exhibits antibacterial activity against Gram-positive bacteria and specifically inhibits Staphylococcus aureus that is resistant to penicillin, streptomycin, neomycin, and macrolide antibiotics.

Paulomycin A (Volonomycin A) exhibits antibacterial activity against Gram-positive bacteria, effectively inhibiting penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-resistant Staphylococcus aureus.

Ashimycin B is a streptomycin analogue that exhibits broad-spectrum antibacterial activity.

Ashimycin A is an analog of Streptomycin with broad-spectrum antibacterial activity.

Senfolomycin A exhibits activity against Gram-positive bacteria and mycobacteria. It is also effective against penicillin-, streptomycin-, neomycin-, and macrolide-resistant Staphylococcus aureus. Additionally, Senfolomycin A has a weaker effect on Gram-negative bacteria.